Clinical Trial

Does Taurine Supplementation Improve Vascular Function and Orthostatic Responses in Long COVID?

Recruiting
View on ClinicalTrials.gov →
Summary
Millions have developed Long COVID (LC), and recent findings show an association between taurine deficiency (an amino acid) and symptoms in LC. Cost-effective and accessible interventions are needed to improve welfare and reduce healthcare costs. We will investigate the efficacy of 12-weeks of taurine supplementation (self-administered), on vascular function and the cardio/cerebrovascular responses to upright posture. We will measure resting vascular function with an EndoPAT device, resting heart rate variability, and the blood pressure, heart rate, and brain blood flow responses to 5 minutes of head-up tilt before and after weeks of taurine supplementation in LC. We hypothesize that the 12 weeks of supplementation will improve both resting vascular function and the responses to upright tilt. In turn, we hypothesize that symptoms will also improve (as measured by questionnaires).
Protocol Amendment History 5 changes
critical Recruitment opened 2026-06-06
critical Phase changed: not applicable -> not specified 2026-06-06
minor Trial arms changed: 1 -> 2 2026-06-06
notable Primary completion pushed: 2026-12-31 -> 2027-06-30 2026-06-06
minor Completion pushed: 2027-03-31 -> 2027-12-31 2026-06-06
Trial Details
NCT Number NCT07312409
Lead Sponsor York University
Collaborators: Canadian Institutes of Health Research (CIHR)
Conditions Long COVID Syndrome
Enrollment 30 participants
Start Date 2026-06-01
Primary Completion 2027-06-30 (estimated)
Study Completion 2027-12-31 (estimated)
Updated on ClinicalTrials.gov 2026-06-05